SCHEMBL5407810

SCHEMBL5407810

O=C(NCc1ccncc1)c1ccc2[nH]ncc2c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.69
METTL3 Q86U44 1/20 0.56
MAPK1 P28482 3/20 0.55
MAPK3 P27361 2/20 0.55
ROCK2 O75116 4/20 0.53
GAA P10253 1/20 0.52
ROCK1 Q13464 2/20 0.52
MMP13 P45452 1/20 0.51
PARP1 P09874 1/20 0.51
RPS6KA5 O75582 1/20 0.50
PRKACA P17612 1/20 0.50
RPS6KB1 P23443 1/20 0.50
PRKX P51817 1/20 0.50
PRKG2 Q13237 1/20 0.50
CLK4 Q9HAZ1 1/20 0.50
SGK2 Q9HBY8 1/20 0.50
PSMD14 O00487 1/20 0.49
STAMBP O95630 1/20 0.49
COPS5 Q92905 1/20 0.49
CA2 P00918 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5441326 0.92 MAOB (0.79) MAOBMETTL3MAPK1ROCK2ROCK1
SCHEMBL5179231 0.88 MAOB (0.70) MAOBMETTL3MAPK1MAPK3ROCK2
SCHEMBL5409324 0.87 MAOB (0.72) MAOBMETTL3MAPK1ROCK2ROCK1
SCHEMBL5407524 0.86 MAOB (0.65) MAOBMETTL3MAPK1ROCK2GAA
SCHEMBL5406113 0.86 MAOB (0.71) MAOBMETTL3MAPK1ROCK2ROCK1
SCHEMBL5413102 0.86 MAOB (0.71) MAOBMETTL3MAPK1ROCK2ROCK1
SCHEMBL5417278 0.86 MAOB (0.71) MAOBMETTL3MAPK1ROCK2ROCK1
SCHEMBL5442402 0.86 MAOB (0.74) MAOBMETTL3MAPK1ROCK2ROCK1
SCHEMBL5412689 0.85 MAOB (0.67) MAOBMETTL3MAPK1ROCK2ROCK1
SCHEMBL5405835 0.84 MAOB (0.68) MAOBMETTL3MAPK1ROCK2ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7199147-B2 Rho kinase inhibitors DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-04-03 US disclosed
US-20040138286-A1 Rho kinase inhibitors DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2004-07-15 US disclosed
EP-1403255-A1 Rho KINASE INHIBITORS SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2004-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138286-A1 Rho kinase inhibitors ROCK1, ROCK2, ARHGDIA MAOB 2025/4885METTL3 3310/4885MAPK1 27/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.